<DOC>
	<DOCNO>NCT02386709</DOCNO>
	<brief_summary>Neoadjuvant chemotherapy frequently propose patient mammary gland cancer . The aim reduce tumor volume surgical therapy . Obtaining pathologic Complete Response ( pCR ) regard good prognostic factor less risk recurrence . The rate pCR 20 % , although important variation accord tumor subtype type treatment . The objective new therapeutic strategy increase response rate . The purpose study investigate possibility early evaluation neoadjuvant chemotherapy response one cycle neoadjuvant chemotherapy positron emission tomography ( PET ) ( 18 ) F-fluorodeoxyglucose ( FDG ) patient .</brief_summary>
	<brief_title>Study Evaluating Utility 18F-FDG PET Assessing Early Response Neoadjuvant Chemotherapy Patients With Mammary Gland Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>patient inform study patient affiliate social health insurance â‰¥ 18 year patient present breast cancer histologically confirm indication neoadjuvant chemotherapy treatment ( classification UICC : II III ) patient agree exploitation clinical , biological image data distant metastasis contraindication chemotherapy contraindication surgery refusal serious illness balance , subjacent infection pregnancy breast feed diabetes control ( glycemia &gt; 8 mmol/L ) psychiatric disease patient supervision , trusteeship safeguard justice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>